Trials / Active Not Recruiting
Active Not RecruitingNCT05896137
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
A Phase II Study to Evaluate Safety, Tolerability and Efficacy, of CS0159 in Patients Subjects With Primary Sclerosing Cholangitis, Multicenter, Randomized, 12-week Double-blind, Placebo-controlled, and 40-week Open Study
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Cascade Pharmaceuticals, Inc · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase II Study of CS0159 in Chinese patients with PSC(Primary Sclerosing Cholangitis)
Detailed description
A phase II study to evaluate safety, tolerability and efficacy, of CS0159 in patients with Primary Sclerosing Cholangitis, this is a multicenter, randomized, 12-weeks double-blind, placebo-controlled, and 40-week open study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS0159 | Oral QD |
Timeline
- Start date
- 2023-08-07
- Primary completion
- 2025-11-14
- Completion
- 2026-05-01
- First posted
- 2023-06-09
- Last updated
- 2026-03-13
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05896137. Inclusion in this directory is not an endorsement.